Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease

J-M Serot, D Christmann, T Dubost, M Couturier

Abstract
The deposition of insoluble β-amyloid protein fibrils is probably the central event in the pathogenesis of Alzheimer’s disease. Cerebrospinal fluid inhibits this fibril formation, likely by the intervention of one or several proteins binding to soluble β-amyloid protein. In vitro, transthyretin (TTR), a CSF protein, impedes amyloid fibrillogenesis. Lowered concentrations of CSFTTR could therefore be associated with Alzheimer’s disease. Concentrations of TTR in CSF samples from 149 consecutive patients were assayed, using a kinetic nephelemetric method. These concentrations were correlated positively with age, but were significantly lower in patients with Alzheimer’s disease. These data raise the possibility that amyloid fibril formation could be promoted in patients with late onset Alzheimer’s disease by the lack of sufficient concentrations of TTR.

Keywords: transthyretin; cerebrospinal fluid; Alzheimer’s disease; aging

Transthyretin (TTR) is a protein of 508 amino acids with a molecular weight of 55 kDa. This tetrameric protein, which occurs in plasma and CSF, is composed of four identical β pleated subunits with a central channel.1 The gene encoding TTR is located on chromosome 18; TTR is synthesised by the liver and, in the brain, only by the epithelial cells of the choroid plexus. In rats, serum TTR concentrations are 10 times higher than TTR concentrations in CSF,2 but the TTR/CSF protein ratio (up to 25% of intraventricular proteins) is much higher than the TTR/serum protein ratio (0.5%). In vitro, TTR constitutes 20% of newly synthesised proteins and 50% of the proteins secreted by the choroid plexus.3 The TTR present in CSF is catabolised by the liver, muscles, and skin, probably after reabsorption by arachnoid villi.1 The CSF-blood barrier prevents the passive diffusion of serum TTR into CSF; therefore TTR in CSF comes almost uniquely from the choroid plexus.4 Concentrations of TTR are nearly the same in ventricular and lumbar CSF.5 The synthesis of serum TTR and TTR in CSF are regulated independently. Fasting reduces serum concentrations whereas CSF concentrations remain unchanged.1 Several TTR mutations have been documented, many of which are associated with systemic or cerebral amyloid deposition; however, none of these mutations are linked to Alzheimer’s disease.1,2 TTR is a transport protein for thyroxin and plasma retinol binding protein. It could have other functions, especially as it sequesters the β-amyloid protein in vitro.3 A decrease of TTR concentration in CSF among severely demented patients with Alzheimer’s disease has been reported.4 To evaluate whether concentrations of TTR in CSF are decreased in Alzheimer’s disease we measured the concentrations in CSF in 149 consecutive patients.

Patients and methods
CSF was obtained from 149 patients: 17 young patients under 20 years old (five males, 12 females, mean age 10.4 (SD 5.4) years), 51 middle aged patients between 20 and 60 years old (21 men, 30 women, mean age 41 (SE 11) years), and among the remaining patients over 60 years old, 41 elderly controls (13 men, 28 women, mean age 76.2 (SD 7.7) years) and 40 patients (13 men, 27 women, mean age 74.2 (SD 5.8) years) with dementia and fulfilling the diagnosis of probable Alzheimer’s disease according to the NINCDS-ADRDA criteria.5 All patients had undergone a lumbar puncture to rule out a neurological disease such as a CNS infection, a subarachnoid haemorrhage, or a degenerative disc disease.

All CSF samples had a protein concentration <0.60 g/l and less than three cells/ml. The TTR concentrations were measured in residual CSF samples after CSF had been examined routinely. Albumin and TTR were assayed by a kinetic nephelemetric method using an automated nephelometer (Beckman Specific Protein Analyzer, Array 360 System; Brea, CA, USA) with antialbumin and anti-TTR antibodies (Beckman Instruments, Galway, Ireland). Samples of CSF were centrifuged before analysis to remove contaminants. Specimens not tested immediately were frozen and stored at −30°. For each assessment series a survey of
Concentrationsof TTR in CSFof controlsubjects (x)andpatients withAlzheimer’sdisease (AD) v controls

<table>
<thead>
<tr>
<th>No</th>
<th>Young controls</th>
<th>Middle aged controls</th>
<th>Elderly controls</th>
<th>Patients with AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>10.4 (5.4)</td>
<td>41.0 (11.0)</td>
<td>76.0 (7.7)</td>
<td>74.2 (5.8)</td>
</tr>
<tr>
<td>51</td>
<td>20–53</td>
<td>61–90</td>
<td>61–88</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>113 (44)***</td>
<td>211 (70)</td>
<td>217 (76)</td>
<td>216 (61)</td>
</tr>
<tr>
<td>40</td>
<td>15.54 (1.82)***</td>
<td>17.37 (2.35)</td>
<td>20.02 (2.45)***</td>
<td>17.49 (2.02)***</td>
</tr>
<tr>
<td>5/12</td>
<td>13/28</td>
<td>13/27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>13/27</td>
<td>13/27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agerange</td>
<td>2–18</td>
<td>20–53</td>
<td>61–90</td>
<td>61–88</td>
</tr>
<tr>
<td>17</td>
<td>51</td>
<td>41</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>211 (70)</td>
<td>217 (76)</td>
<td>216 (61)</td>
<td></td>
</tr>
<tr>
<td>211 (70)</td>
<td>217 (76)</td>
<td>216 (61)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mean (SD) albumin (mg/l)* 113 (44)*** 211 (70) 217 (76) 216 (61)

Mean (SD) TTR (mg/l)* 15.54 (1.82)*** 17.37 (2.35) 20.02 (2.45)*** 17.49 (2.02)

***P<0.001 v patients with AD.

standardisation with pre-established dilutions (Vigil PRX, Beckman Instruments, Brea, CA, USA) was performed.

Statistical analysis using Student’s t tests was performed with the Slide Write Plus software (Carlsbad, CA, USA). Significance was considered for P values <0.05.

Results

In the younger control group the mean concentration of TTR in CSF was 15.54 (SD 1.82) mg/l, significantly different (P<0.0001) from the mean concentration in the elderly control group (20.02 (SD 2.45) mg/l) and in the middle aged control group (17.37 (SD 2.35) mg/l; P<0.001). The concentration of TTR in CSF in patients with Alzheimer’s disease (17.49 (SD 2.02) mg/l) was not significantly different from that of middle aged patients (P=0.8), but significantly lower than that of aged control patients (P<0.0001). The table summarises these results.

Concentrations of TTR in CSF increased progressively with aging, at a rate of 0.06 mg/l every year (figure).

The mean concentration of albumin in CSF was lower in young patients (113 (SD 44) mg/l) than in middle aged patients (211 (SE 70) mg/l). It was not different in patients with Alzheimer’s disease (216 (SD 61) mg/l) and in the elderly control group (217 (SD 76) mg/l).

Discussion

This study reports an increase in concentration of TTR in CSF with age, except in patients with Alzheimer’s disease, who display significantly lower concentrations despite some overlap between patients with Alzheimer’s disease and aging controls.

The increase in concentration of TTR in CSF with age could be evaluated at 0.06 mg/l per year in our study, a feature previously reported by others but unexplained. Concentrations of TTR in CSF result from simultaneous phenomena: secretion and filtration by the choroid plexus, passive diffusion through the blood-CSF barrier, and reabsorption. Albumin has a molecular weight of 65 kDa, in the same range as TTR. According to some authors (for review see Kalaria), albumin concentrations rise in the CSF of aging patients, although serum albumin concentrations decrease, suggesting an increased blood-CSF barrier leak, particularly in the case of leukoaraiosis. Other authors have reported that CSF albumin concentrations do not increase with age, and our study similarly shows no change. This seems to indicate that the increase of TTR concentrations in CSF with age is not due to a disorder of the blood-CSF barrier permeability. Indeed May et al reported a decrease in CSF filtration rates from 0.41 ml/min at 28 years of age to 0.19 ml/min at 77 years of age, probably related to modifications of the choroid plexus, such as thickened stroma, appearance of psammomas and cysts, and increased thickness of the epithelial basement membrane. All these features could support a reduction of CSF filtration in elderly people.

In patients with Alzheimer’s disease, concentrations of TTR in CSF were lower than in aging control subjects whereas albumin concentrations in CSF were in the same range, indicating a decrease of TTR secretion. This hypothesis is consistent with several other features. For instance, in rats, chronic lead exposure impairs the function of CP, and concentrations of TTR in CSF are decreased. The epithelium of the choroid plexus transports vitamin B12 from blood into CSF, and vitamin B12 concentrations have been reported to be lowered in the CSF of patients with Alzheimer’s disease. Isotopic scintigraphy detects hydraulic anomalies in CSF in patients with Alzheimer’s disease such as reversal flow with ventricular reflux or delayed clearance. Histological studies performed on the choroid plexus in Alzheimer’s disease have reported an important stromal fibrosis, and the height of choroid plexus epithelial cells is significantly higher in elderly controls than in patients with Alzheimer’s disease. The deposition of β-amyloid fibrils is probably a central event in the pathogenesis of Alzheimer’s disease, and sequestration of β-amyloid protein has been reported to prevent amyloid formation. In vitro, CSF inhibits β-amyloid fibril formation, and it has been suggested that this phenomenon could be related to its interaction with one or several sequestering proteins such as α-1-antichymotrypsin, apolipoproteins E (apoE) and J (apoJ), or TTR. Indeed, α-1-antichymotrypsin is able to prevent β-amyloid fibrillogenesis in vitro, and could induce fibril formation.
An interaction between ApoE and β-amyloid is suggested by the fact that ApoE immunoreactivity is found in senile plaques, and because this lipoprotein prevents β-amyloid aggregation in vitro. The β-amyloid/ApoE interaction is influenced by the β sheet conformation of the amyloid peptides used and by the purification of ApoE. The more important avidity of the native ApoE3 allele products is attenuated by epithelial atrophy in the choroid plexus in patients with leucoracous: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993;115:125–31.


